Zoetis Inc. $ZTS Shares Sold by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 83.6% during the 1st quarter, Holdings Channel reports. The fund owned 3,771 shares of the company’s stock after selling 19,288 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Zoetis were worth $446,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Louisiana State Employees Retirement System acquired a new position in shares of Zoetis in the 1st quarter valued at $2,542,000. Deutsche Bank AG increased its holdings in shares of Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after buying an additional 891,921 shares during the last quarter. Seilern Investment Management Ltd increased its holdings in shares of Zoetis by 361.2% during the 4th quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after buying an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of Zoetis by 134.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after buying an additional 935,432 shares during the period. Finally, Pincus Capital Management LP purchased a new position in shares of Zoetis in the 4th quarter worth $2,109,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $76.17 on Tuesday. Zoetis Inc. has a fifty-two week low of $71.47 and a fifty-two week high of $160.48. The business has a 50 day moving average price of $77.32 and a two-hundred day moving average price of $105.54. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a market cap of $31.93 billion, a PE ratio of 12.63, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company earned $1.48 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. HSBC lowered their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. JPMorgan Chase & Co. reduced their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a research note on Friday, May 15th. UBS Group dropped their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Finally, Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $120.83.

Insider Activity at Zoetis

In related news, Director Frank A. Damelio acquired 6,650 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 11,650 shares of company stock valued at $886,384 over the last ninety days. Corporate insiders own 0.22% of the company’s stock.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis saw unusual options activity, with traders buying 8,095 call options, about 59% above the average daily volume, suggesting some speculative bullish interest.
• Neutral Sentiment: Several law firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter LLP, the Schall Law Firm, Bronstein Gewirtz & Grossman LLC, DJS Law Group, and Bragar Eagel & Squire, reminded investors about a July 27 lead-plaintiff deadline in an existing class action related to Zoetis securities purchased between January 14, 2025 and May 6, 2026. Article Title
• Negative Sentiment: The class-action campaign keeps attention on alleged securities-law violations, which can create legal uncertainty and pressure the stock until the case is resolved. Article Title

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.